Patients who swtich from Pfizer’s (PFE) monster selling drug cholesterol pill Lipitor to Merck’s (MRK) Zocor, now available in generic form are more likely to have a heart attack or die.
According to Reuters: "The conclusion was that switching was associated with a 30 percent increase in the relative risk of major cardiovascular events, including heart attacks, strokes and death."
Of course, the study was back by Pfizer. Hard to say how it would have come out otherwise.
Douglas A. McIntyre